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mTORC1 plays an important 
role in osteoblastic regulation of 
B-lymphopoiesis
Sally K. Martin1,2, Stephen Fitter1,2, Nadia El Khawanky2,3,4, Randall H. Grose2,  
Carl R. Walkley  5, Louise E. Purton  5, Markus A. Ruegg6, Michael N. Hall6,  
Stan Gronthos  2,7 & Andrew C. W. Zannettino1,2
Skeletal osteoblasts are important regulators of B-lymphopoiesis, serving as a rich source of factors 
such as CXCL12 and IL-7 which are crucial for B-cell development. Recent studies from our laboratory 
and others have shown that deletion of Rptor, a unique component of the mTORC1 nutrient-sensing 
complex, early in the osteoblast lineage development results in defective bone development in mice. 
In this study, we now demonstrate that mTORC1 signalling in pre-osteoblasts is required for normal 
B-lymphocyte development in mice. Targeted deletion of Rptor in osterix-expressing pre-osteoblasts 
(Rptorob−/−) leads to a significant reduction in the number of B-cells in the bone marrow, peripheral 
blood and spleen at 4 and 12 weeks of age. Rptorob−/− mice also exhibit a significant reduction in 
pre-B and immature B-cells in the BM, indicative of a block in B-cell development from the pro-B to 
pre-B cell stage. Circulating levels of IL-7 and CXCL12 are also significantly reduced in Rptorob−/− mice. 
Importantly, whilst Rptor-deficient osteoblasts are unable to support HSC differentiation to B-cells 
in co-culture, this can be rescued by the addition of exogenous IL-7 and CXCL12. Collectively, these 
findings demonstrate that mTORC1 plays an important role in extrinsic osteoblastic regulation of B-cell 
development.
From late embryogenesis onwards, the bone marrow (BM) is the primary site of haematopoietic stem cell (HSC) 
self-renewal and differentiation. The process of HSC differentiation into the various blood cell types is tightly reg-
ulated by the BM microenvironment, which consists of stromal cells (osteoblasts, endothelial cells, macrophages, 
fibroblasts, adipocytes), extracellular matrix and soluble regulatory factors. In recent years, researchers have 
investigated the specific contribution of individual BM cell types to the HSC niche and so far, the greatest impor-
tance has been attributed to bone-forming osteoblasts and the vasculature (reviewed in1,2).
Anatomically, quiescent HSCs reside close to the endosteal surface of the trabecular bone in an HSC reservoir 
that can be mobilised in response to physiological demand or tissue injury. Osteoblast cells secrete several fac-
tors (e.g. angiopoietin, BMP4, thrombopoietin, CXCL12) that are important for HSC self-renewal, survival and 
maintenance. The selective ablation of osteoblasts in vivo leads to a dramatic reduction in BM cellularity and hae-
matopoiesis3 and conversely, when the number of osteoblasts are experimentally increased in vivo, a concomitant 
increase in the BM HSC pool size, but not the hematopoietic cell pool size, is observed4,5.
Beyond its support for HSCs, osteoblasts are also important for the support of differentiated haematopoietic 
cells such as B-cells. Osteoblasts have been shown to support all stages of B-cell development in vitro, from the 
first transition of HSCs to the common lymphoid progenitor to the generation of mature IgM+ B-cells6. When 
endosteal osteoblasts are conditionally ablated in vivo, B-cell lymphopoiesis is abruptly and drastically reduced3,6.
The BM microenvironment contains distinct niches for each stage of B-lymphocyte development. 
B-lymphocytes originate from HSCs through a common lymphoid progenitor. The earliest identifiable B-cell 
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precursor in the BM are prepro-B cells, which sequentially differentiate into pro-B cells, pre-B cells and immature 
B-cells. These immature B-cells then migrate into the periphery, where final maturation occurs in the spleen7–12. 
Within the BM microenvironment, CXCL12 and interleukin (IL)-7, two factors that are important in B-cell devel-
opment4,6,13, are expressed by distinct stromal cell populations. Importantly, prepro-B cells are found in close 
proximity to CXCL12-expressing cells, whereas the more differentiated pro-B cells are found in contact with 
IL-7-expressing cells14. These findings suggest that as B-cell precursors differentiate, they migrate between dis-
crete populations of supporting stromal cells in the BM microenvironment.
Bone cells arise from multipotent mesenchymal stem cells which, in response to specific cues, undergo 
sequential differentiation into osteoprogenitors, pre-osteoblasts, mature osteoblasts and terminally-differentiated 
osteocytes. Conditional deletion of CXCL12 in osteoprogenitors, but not mature osteoblasts, results in a marked 
loss of early B-cell progenitors15, and ablation of the Gs-alpha subunit of the parathyroid receptor in osteoprogeni-
tors, but not mature osteoblasts, results in impaired B-lymphopoiesis16,17. This suggests that osteoprogenitors, and 
not mature osteoblasts, play a crucial role in B-lymphopoiesis.
Most cellular processes that govern growth require activation by anabolic signals. Mammalian target of rapa-
mycin (mTOR) is an evolutionarily conserved kinase that functions in two structurally and functionally distinct 
multiprotein complexes, termed mTORC1 and mTORC2, which are defined by the unique adaptor proteins raptor 
and rictor, respectively. Activated by major intracellular and extracellular stimuli, mTORC1 controls protein syn-
thesis, ribosome biogenesis and nutrient transport through the activation of downstream effectors p70S6K and 
4-EBP118,19. Notably, recent studies from our laboratory20 and others21,22 have shown that conditional deletion of 
mTORC1 in pre-osteoblast cells (Rptorob−/−) results in a marked reduction in pre- and post-natal bone accrual, 
reduced limb length and increased skeletal fragility due to a reduction in osteoblast function. In light of the prom-
inent skeletal phenotype of Rptorob−/− mice and the critical role that osteoblasts play in B-cell development, we 
hypothesised that osteoblastic mTORC1 may also play an important role in regulating B-lymphocyte development 
in vivo. To investigate this, we examined B-lymphopoiesis in our Rptorob−/− mice and found a significant reduction 
in the number of B-lymphocytes in the bone marrow, spleen and peripheral blood. Furthermore, we found that 
the mTORC1-dependent regulation of B-lymphopoiesis by osteoblastic cells is mediated by CXCL12 and IL-7.
Results
Conditional Ablation of Rptor in Osteoblast Precursors leads to Impaired B Lymphopoiesis. 
Rptor, a unique and essential component of mTORC1, was ablated in osteoblast precursor cells using transgenic 
mice in which Cre recombinase is driven by the osterix promoter, a transcription factor expressed early in osteo-
blastogenesis (Osx1-GFP::Cre)23. These mice were mated with mice harbouring loxP sites flanking exon 6 of the 
Rptor gene (Rptorfl/fl)24 and a floxed stop R26-stop-EYFP reporter25 to produce heterozygous (eYFP-Rptorob+/−) 
and homozygous (eYFP-Rptorob−/−) Rptor knockout mice20. In light of the distinct skeletal phenotype of Osx1-
GFP::Cre mice20,26–28, eYFP-Osx:Cre transgenic mice (as opposed to wild type littermates) were used as controls 
for all experiments. Furthermore, as we have previously shown a gene dosage effect in mice with deletion of one 
or both alleles of Rptor in pre-osteoblasts20, heterozygous littermates were also included in all analyses.
To determine whether the loss of Rptor affects the ability of osteoblasts to support haematopoietic develop-
ment, we analysed the frequency of mature haematopoietic lineages in the BM of heterozygous (eYFP-Rptorob+/−) 
and homozygous (eYFP-Rptorob−/−) knockout mice using flow cytometry. For these studies, animals were ana-
lysed at both 4 and 12 weeks of age as they represent early and later phase of long-bone growth in mice29. As 
eYFP-Rptorob−/− mice are significantly smaller than eYFP-Osx:Cre controls at both 4 and 12 weeks of age20, the 
distribution of each lineage was calculated as a percentage of total BM cells in order to account for the reduced 
skeletal size and bone marrow cellularity of eYFP-Rptorob−/− mice. At both time points, a significant reduc-
tion in B220+ B-cells was observed in the BM of eYFP-Rptorob−/− knockout mice compared to eYFP-Osx:Cre 
controls (Fig. 1A,B). At 4 weeks of age, no significant difference in CD3+ T-cells was observed in the BM of 
eYFP-Rptorob−/− mice, whereas CD11b+/Gr1+ myeloid cells were increased (Fig. 1A). In contrast, a significant 
reduction in CD3+ T-cells and a significant increase in CD11b+/Gr1+ myeloid cells was observed in 12-week 
old eYFP-Rptorob−/− mice compared to controls (Fig. 1B). Notably, the B-cell defect observed in the BM of 
eYFP-Rptorob−/− knockout mice was accompanied by a significant reduction in the number of B220+ B-cells in 
the peripheral blood circulation (Fig. 1C) and the spleen (Fig. 1D) at both 4 and 12 weeks of age. A significant 
reduction in B220+ B-cells in the peripheral blood circulation and spleen of heterozygous eYFP-Rptorob+/− mice 
relative to controls was also observed at 12 weeks of age, suggestive of a gene dose effect (Fig. 1C,D).
Whilst the spleens of 4-week old eYFP-Rptorob−/− mice were markedly smaller than eYFP-Osx:Cre con-
trols, this was not statistically significant (p = 0.64) when corrected for body weight (Fig. 2A). Intriguingly, 
eYFP-Rptorob−/− spleen weights were significantly reduced compared to the heterozygous eYFP-Rptorob+/− knock-
out mice, due to a modest increase in weight-adjusted spleen weight in the eYFP-Rptorob+/− mice compared to 
eYFP-Osx:Cre controls (Fig. 2A). Whilst eYFP-Rptorob+/− and eYFP-Rptorob−/− mice displayed reduced spleen 
weights compared to eYFP-Osx:Cre controls at 12 weeks of age, this was not statistically significant (p = 0.42 and 
p = 0.55 respectively, Fig. 2A). Within the spleen, the proliferation and differentiation of B-lymphocytes occurs 
in lymphoid follicles, the major component of the white pulp (Fig. 2B,C). While histological analysis revealed no 
difference in splenic white pulp area in eYFP-Rptorob+/− and eYFP-Rptorob−/− knockout mice compared to con-
trols (Fig. 2D), the number of white pulp follicles was significantly increased in eYFP-Rptorob−/− at 4 weeks of age 
(Fig. 2E). As a result, the average size of the white pulp follicles in these mice was significantly reduced in 4-week 
old mice (Fig. 2F).
B-Lymphopoiesis is Impaired Along the Pro-B to Pre-B Cell Transition in eYFP-Rptorob+/− and 
eYFP-Rptorob−/− Knockout Mice. During B-lymphopoiesis, commitment of the common lymphoid 
progenitor to the B-cell lineage is marked by the expression of B220, followed by sequential differentiation to 
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prepro-B, pro-B and pre-B cells and ultimately, immature B-cells. These immature B-cells then leave the BM for 
the final stages of their maturation in secondary lymphoid organs to form end-stage antibody-producing plasma 
cells which, upon activation by antigen-presentation, return and colonise the BM7–12. To investigate whether 
impaired B-lymphopoiesis is responsible for the reduced numbers of B220+ B-cells in eYFP-Rptorob+/− and 
eYFP-Rptorob−/− mice, the relative proportion of prepro-B, pro-B, pre-B and immature B-cells in the BM, spleen 
and peripheral blood circulation was assessed using CD19, CD43, IgM and B220 phenotypic markers (Fig. 3A; 
Supplementary Fig. 1). As shown in Fig. 3B, the percentage of pro-B cells, pre-B cells, and immature B-cells was 
significantly reduced in the BM of eYFP-Rptorob−/− mice at both 4 and 12 weeks of age. This reduction in pre-B 
and immature B cells was also observed in the peripheral blood circulation and the spleen of eYFP-Rptorob−/− 
mice albeit at 12 weeks of age only (Fig. 3C,D). Furthermore, this reduction was also evident in heterozygous 
eYFP-Rptorob+/− mice, consistent with a gene dose effect. Unlike the BM, there was no significant change in the 
number of pro-B cells in the peripheral blood or spleen irrespective of genotype or age (Fig. 3C,D). Interestingly, 
there was a significant increase in the number of prepro-B cells in the spleens of both heterozygous and homozy-
gous mice, relative to controls, at 12 weeks of age (Fig. 3D). These data suggest that mTORC1 signalling in 
pre-osteoblasts has a profound effect on B-cell development.
CXCL12 and IL-7 mRNA Expression is Decreased in Rptor-Deficient Osteoblasts. Skeletal oste-
oblasts are a rich source of trophic factors which regulate B-lymphopoiesis. CXCL12, an important regulator 
of early B-cell development, is important for prepro-B cell development9. In contrast, IL-7 is an important reg-
ulator of late B-cell development and is crucial for the production of pro-B and pre-B cells30,31. To identify the 
potential mechanisms by which pre-osteoblast mTORC1 signalling regulates B-lymphopoiesis, we assessed tran-
script levels of Cxcl12 and Il7 in eYFP+ cells (ie. osteoprogenitors, mature osteoblasts and osteocytes harbouring 
Cre-mediated recombination) recovered from the long bones of 4-week old eYFP-Osx:Cre, eYFP-Rptorob+/− and 
eYFP-Rptorob−/− mice. Cxcl12 and IL7 mRNA levels were significantly reduced in eYFP-Rptorob−/− osteoblasts 
compared to controls (Fig. 4A: mean decrease 39.5 ± 2.2%; and Fig. 4B: mean decrease 62 ± 6.1%). In contrast, 
for heterozygous eYFP-Rptorob+/− mice, transcript levels of Cxcl12 were increased and no change in Il7 tran-
script levels, relative to controls, was observed (Fig. 4A,B). Despite the genotype-specific differences in transcript 
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Figure 1. B-Lymphopoiesis is impaired in eYFP-Rptorob+/− and eYFP-Rptorob−/− mice at 4 and 12 weeks of age. 
The frequency of B-cells, T-cells and myeloid cells in the bone marrow (BM) of (A) 4-week old and (B) 12-week 
old eYFP-Osx:Cre (CRE), eYFP-Rptorob+/− (HET), and eYFP-Rptorob−/− (HOM) mice was assessed using flow 
cytometry (n = 4–5/group). Data are expressed as percentage of total bone marrow cells. (C) The percentage 
of B220+ B-lymphocytes in the peripheral blood (PB) of 4- and 12-week old mice (n = 4–5/group). (D) The 
percentage of B220+ B-lymphocytes in the spleens of 4- and 12-week old mice (n = 4–5/group). Data are 
expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, one-way ANOVA with Tukey’s 
post-hoc test.
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levels a significant reduction in circulating CXCL12 levels was evident in 4- and 12-week old eYFP-Rptorob+/− 
and eYFP-Rptorob−/− mice compared to controls (Fig. 4C). Circulating IL-7 levels were significantly reduced in 
eYFP-Rptorob−/− mice compared to controls at 12 weeks of age only (Fig. 4D).
Rptor deficient osteoblasts fail to support HSC differentiation to B-cells in vitro, but this can 
be rescued by exogenous Flt3L, IL-7 and CXCL12. To confirm that the abnormal B-lymphopoiesis 
observed in the eYFP-Rptorob−/− mice is directly attributable to Rptor deficiency in osteoblasts, we next examined 
the ability of wild type and Rptor-deficient osteoblasts to support the differentiation of purified haematopoietic 
stem cells (LSK cells) into B-cell precursors. To achieve this, primary calvarial MSCs were isolated from neonatal 
Rptorfl/fl mice and infected with a tamoxifen-inducible self-deleting Cre recombinase (CreERT2). CreERT2-infected 
cells were then treated with or without tamoxifen for 8 days to induce Rptor deletion (RapKO) or vehicle con-
trol (WT) MSCs. These WT and RapKO MSCs were then cultured under osteoinductive conditions to produce 
RapKO and WT osteoblasts as previously described6.
When BM LSK cells from wild type C57BL/6 mice were added to these osteoblast monolayers, approximately 
42% of the haematopoietic cells recovered from the WT osteoblast co-cultures were B220+ after 10 days com-
pared to only 29% of the cells recovered from RapKO osteoblast co-cultures (Fig. 5A: mean decrease 31.7 ± 1.5%). 
Importantly, the addition of exogenous IL-7 and CXCL12 to these co-cultures restored the ability of RapKO 
osteoblasts to support B lymphopoiesis, with 49% and 51% of the haematopoietic cells recovered from WT and 
RapKO osteoblast co-cultures found to be B220+, respectively (Fig. 5A).
Using CD19, CD43 and IgM phenotypic markers, the relative proportion of prepro-B, pro-B, pre-B and imma-
ture B-cells within the B220+ cells isolated from the osteoblast-LSK co-cultures was also examined. As shown in 
Fig. 5B, in the absence of exogenous factors, the percentage of prepro-B cells was significantly increased in RapKO 
osteoblast co-cultures compared to WT co-cultures (mean increase: 115.47 ± 17%), whereas the percentages of 
pro-B, pre-B and immature-B cells were reduced. Importantly, the addition of exogenous IL-7 and CXCL12 to 
these co-cultures restored the ability of RapKO osteoblasts to support LSK differentiation into pre-B and imma-
ture B-cells as evidenced by a factor-dependent normalisation of prepro-B cell numbers and a significant increase 
in the percentage of pro-B, pre-B and immature B cells (Fig. 5B).
Discussion
Stromal cells within the BM microenvironment, such as osteoblasts, endothelial cells, adipocytes and fibroblasts, 
are crucial for HSC development. Beyond its support for HSC precursors, the BM stroma also provides a specific 
niche for lineage-committed haematopoietic cells such as B-lymphocytes14. Recent studies from our laboratory 
and others have demonstrated that mTORC1 signalling pathways play an important role in skeletal development, 
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Figure 2. Loss of mTORC1 function is pre-osteoblasts affects spleen size and structure. (A) Spleen weights, 
normalised to total body weight, of 4- and 12-week old mice (n = 10–15/group). Representative haematoxylin 
and eosin-stained spleen sections from (B) 4-week old and (C) 12-week old eYFP-Osx:Cre (CRE), eYFP-
Rptorob+/− (HET), and eYFP-Rptorob−/− (HOM) mice (4x magnification). The dotted white outlines indicate 
white pulp. (D) Quantitation of total white pulp area, expressed as a percentage of total spleen area, in 4- and 
12-week old mice (n = 10/group). (E) Quantitation of white pulp follicle number, normalised to total spleen 
area analysed, in 4- and 12-week old mice (n = 10/group). (F) Quantitation of white pulp follicle size, in 4- and 
12-week old mice (n = 10/group). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, one-way ANOVA 
with Tukey’s post-hoc test.
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with bone-specific knockout of mTOR32 and Rptor20–22 leading to impaired postnatal bone acquisition and con-
versely, bone-specific knockout of tuberous sclerosis complex 2 (TSC-2, negative regulator of mTORC1)32 causing 
a progressive increase in postnatal bone acquisition. Considering the well-established role that osteoblasts play in 
supporting haematopoiesis and B-cell development3,6, we hypothesised that skeletal mTORC1 signalling plays an 
important role in supporting B-cell development.
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Figure 3. Impaired B-Lymphopoiesis in eYFP-Rptorob+/− and eYFP-Rptorob−/− mice is due to a stall in the 
Pro-B to Pre-B Cell Transition. (A) Immunophenotypic expression markers used to distinguish B220+ B cell 
subsets. Cells isolated from (B) the bone marrow (BM), (C) peripheral blood (PB) and (D) spleen of 4- and 
12-week old eYFP-Osx:Cre (CRE), eYFP-Rptorob+/− (HET), and eYFP-Rptorob−/− (HOM) mice (n = 4–5/
group) were stained with antibodies directed against the B-cell phenotypic markers CD19, CD43, IgM and 
B220. The number of prepro-B cells (B220+IgM−CD19−CD43+), pro-B cells (B220+IgM−CD19+CD43+), 
pre-B cells (B220+IgM−CD19+CD43−), and immature B-cells (B220+IgM+CD19−CD43−) present within each 
compartment was analysed using flow cytometry. Data are expressed as percentage of B220+ cells, mean ± SEM. 
*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, one-way ANOVA with Tukey’s post-hoc test.
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In this study, we showed that the deletion of Rptor in Osterix-expressing cells has a profound effect on B-cell 
development, with a significant reduction in the number of pro-B, pre-B and immature B-cells observed in the 
BM of eYFP-Rptorob−/− mice compared to eYFP-Osx:Cre controls at both 4- and 12-weeks of age. This defect in 
B-cell development within the BM was accompanied by a reduction in the number of circulating pre-B and imma-
ture B cells in the blood. The substantial change in the proportion of B-cell precursors in our eYFP-Rptorob−/− 
mice was due to a stall in B-cell development between the pro-B to pre-B cell transition.
We also showed that eYFP+ bone cells isolated from eYFP-Rptorob−/− KO mice express significantly lower 
levels of Cxcl12 and Il-7 transcript compared to eYFP-Osx:Cre controls, and display a concomitant decrease in 
CXCL12 and IL-7 protein levels in the peripheral blood circulation. Given the well-established role of IL-7 in 
the differentiation of pro-B cells30,31, the reduced levels of IL-7 expression observed in osteoblasts isolated from 
eYFP-Rptorob−/− mice was consistent with the defect in B-lymphopoiesis at the pro-B to pre-B transition in these 
mice. The significant reduction in CXCL12 expression however, in the absence of any defect in prepro-B cell 
production in the BM, was somewhat surprising and raises the possibility that other factors may compensate 
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with exogenous CXCL12 and IL-7. The ability of wild type (WT) and Rptor-deficient osteoblasts (RapKO) to 
support B-lymphopoiesis in vitro was examined by co-culturing Lin−Sca-1+c-kit+ (LSK) cells on osteoblast 
monolayers in the presence or absence of exogenous growth factors. (A) The percentage of B220+ cells 
arising from in vitro co-culture was examined by flow cytometry. Data are expressed as a percentage of total 
haematopoietic cells. *p < 0.05, ***p < 0.005, one-way ANOVA with Tukey’s post-hoc test. (B) Haematopoietic 
cells recovered from WT and RapKO osteoblast co-cultures (in the presence or absence of exogenous growth 
factors) were stained with antibodies directed against the B-cell phenotypic markers CD19, CD43, IgM and 
B220. The number of prepro-B cells (B220+IgM−CD19−CD43+), pro-B cells (B220+IgM−CD19+CD43+), pre-B 
cells (B220+IgM−CD19+CD43−), and immature B-cells (B220+IgM+CD19−CD43−) was analysed using flow 
cytometry. Data are expressed as a percentage of B220+ cells, mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, 
****p < 0.001, two-way ANOVA with Tukey’s multiple comparisons post-hoc test.
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for the loss of CXCL12 in the early stages of B-lymphopoiesis in these mice. CXCL12 is important for the for-
mation of distinct niches in the bone marrow that support life-long generation of B lymphocytes by acting as a 
chemoattractant for CXCR4-expressing progenitors33. It is therefore interesting to note that the level of splenic 
prepro-B cells was elevated in 12-week old eYFP-Rptorob−/− mice. As these cells are typically restricted to the BM, 
an increase in splenic prepro-B cells could reflect a change to the B cell supportive niche that allows extravasation 
of progenitor cells to the spleen. Moreover, modification of bone marrow niche may also account for the reduc-
tion in T cells and increase in myeloid cells in eYFP-Rptorob−/− mice.
Whilst this manuscript was under preparation, a study by Wang and colleagues showed that the deletion 
of Rptor in Osx-expressing pre-osteoblasts, and not mature Ocn-expressing osteoblasts, leads to impaired 
B-lymphopoiesis34. In this study, the authors showed that 3-week-old homozygous Osx-Rptor KO mice display 
impaired B-cell differentiation and a block in B-cell development in the Pro-B to Pre-B transition, with this defect 
attributed to pre-B and immature B-cell apoptosis induced by abnormal IL-7/Stat5 signalling. A key difference 
between the Wang et al., study and this current study is the genotype of the control mice. We have compared 
eYFP-Rptorob−/− and eYFP-Rptorob+/− to eYFP-Osx:Cre mice (i.e. a control strain harbouring two wild type Rptor 
alleles), whereas Wang et al. compared the phenotype of homozygous Rptor KO mice to heterozygous Rptor 
KO mice. Given the well-documented skeletal phenotype of tTA:Osx:Cre mice20,26–28 and potential non-skeletal 
Sp7 (Osterix) expression in the olfactory bulb and intestinal epithelia35, eYFP-Osx:Cre mice are an indispensible 
control for Osx-Cre-driven conditional gene deletion models. Indeed, as shown here, the observed perturbations 
in the BM, spleen and peripheral blood compartments of eYFP-Rptorob−/− mice were often magnified when com-
pared to the eYFP-Osx:Cre control, and in some instances the inclusion of the eYFP-Osx:Cre control revealed 
differences that were not apparent when comparing to heterozygous KO animals alone.
Importantly, the comparison of eYFP-Rptorob−/− and eYFP-Rptorob+/− with eYFP-Osx:Cre control mice has 
enabled us to assess the effect of Rptor gene dose in pre-osteoblasts in the regulation of B-lymphopoiesis. As 
demonstrated herein, loss of one allele of Rptor in pre-osteoblasts is sufficient to cause significant alterations to 
the frequency and tissue distribution of B-cell subsets. This pattern of disruption does not mirror that observed 
in eYFP-Rptorob−/− mice, suggesting distinct cellular responses to the loss of one vs. two alleles. We observed a 
similar gene dose effect when comparing the skeletal phenotypes of eYFP-Rptorob+/− and eYFP-Rptorob−/− mice 
with eYFP-Osx:Cre mice, where deletion of one Rptor allele resulted in a less severe loss of bone mass and bone 
strength compared to deletion of both Rptor alleles20. Phenotypes arising from the reduction (loss of one allele 
of Rptor) or complete (homozygous deletion of Rptor) loss of mTORC1 function in pre-osteoblasts are complex 
as mTORC1 plays an important role in negative feedback loops that control signal transduction pathways. In 
response to insulin, mTORC1 directly and indirectly phosphorylates insulin receptor substrate 1 (IRS-1), leading 
to its degradation36. mTORC1 also activates growth factor receptor-bound protein 10 (Grb10), which inhibits 
IRS1 from binding to activated insulin receptor (InsR)37. Thus perturbations in mTORC1 function can lead to 
hyper-stimulation of signalling pathways which contribute to phenotype complexity.
We have previously shown that osteoblasts derived from eYFP-Rptorob−/− knockout mice have a reduced oste-
ogenic potential and a transcriptional profile consistent with an immature osteoblast phenotype, indicating that 
Rptor deletion leads to a stall in early osteogenic differentiation20. These cells also have reduced protein syn-
thetic capacity, which likely inhibits their capacity to differentiate into mature osteoblasts. Thus, we postulate 
that mTORC1-mediated translational control contributes to IL-7 and CXCL12 production in osteoblasts and is 
responsible for the impaired B-lymphopoiesis observed in response to osteoblastic mTORC1 inhibition.
In addition to playing an essential role in the maintenance and differentiation of HSCs, OBs have been shown 
to play a role in suppressing haematological malignancies. Osteoblast numbers are significantly decreased in 
patients with myelodysplasia and acute myeloid leukemia38, and genetic depletion of osteoblasts in murine mod-
els of acute leukemia results in an increase in circulating blasts and tumor engraftment38. Global disruption of 
gene expression by deletion of Dicer1 in osteoprogenitors results in impaired osteoblastic differentiation and the 
development of myelodysplasia with the propensity to develop acute myeloid leukemia (AML)39. Similarly, con-
stitutive activation of β-catenin signaling, specifically in osteoblast progenitors alters the differentiation potential 
of myeloid and lymphoid progenitors leading to the development of AML40. These findings demonstrate that 
critical changes in the signaling pathways that govern normal osteoblast function can contribute to aberrant hae-
matopoiesis. Therefore, gaining a greater understanding of osteoblastic signaling pathways that are important for 
maintaining normal haematopoiesis could reveal important therapeutic targets for haematopoietic malignancies.
In summary, our findings demonstrate that mTORC1 signalling in osteoprogenitor cells is crucial to the reg-
ulation of B-lymphopoiesis by cells of the osteoblast lineage. Given the propensity for malignant disorders of the 
B-cell lineage (e.g. multiple myeloma) to involve the skeleton, these findings lay the foundation for future studies 
involving the pathophysiology of these disorders and offer novel therapeutic approaches.
Materials and Methods
Transgenic mice. All mice were bred and housed at the SA Pathology Animal Care Facility and all studies 
performed with Institutional Ethics approval (SA Pathology/CALHN, #102/12) and were performed in accord-
ance with relevant guidelines and regulations. Conditional knockout mice in which Rptor, a unique and essen-
tial component of mTORC1, was disrupted in early osteoprogenitor cells were generated using Osx1-GFP::Cre 
mice23, R26eYFP mice25 and Rptorfl/fl mice24 as previously described20. In all studies, Osx1-GFP::Cre (designated 
eYFP-Osx:Cre) mice were used as controls. Heterozygous (Osx1-GFP::Cre-Rosa26eYFP-Rptor+/fl, designated 
eYFP-Rptorob+/−) and homozygous (Osx1-GFP::Cre-Rosa26eYFP-Rptorfl/fl, designated eYFP-Rptorob−/−) knockout 
mice were born at the expected Mendelian frequencies and at birth, no gross phenotypic differences or difference 
in weight or length was evident in knockout animals, relative to age-matched eYFP-Osx:Cre controls20. For all 
studies, equal numbers of male and female mice were used in each group.
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Hematopoietic B-cell Staining and Flow Analysis. Bone marrow, spleen and peripheral blood cells 
were isolated from 4- and 12-week-old eYFP-Osx:Cre, eYFP-Rptorob+/− and eYFP-Rptorob−/− mice (n = 5–8 per 
group). Peripheral blood was haemolysed by osmotic lysis using ammonium chloride buffer (150 mM NH4Cl, 
10 mM KHCO3, 0.1 mM EDTA, pH 7.3) on ice for 10 minutes. BM, spleen and peripheral blood cells were 
stained with antibodies to B-lymphocytes (B220, IgM), T-lymphocytes (CD3e) and granulocytes (CD11b, Gr-1). 
B-cell precursors were analysed with antibodies to CD19-APC (clone 1D3, eBioscience, CA, USA), CD43-PE 
(clone 2/60, eBioscience), IgM-PE-Cy7 (clone R6-60.2, BD Bioscience, NJ, USA), B220-biotin (clone RA3-6B2, 
BioLegend, CA, USA) and streptavidin-FITC (Southern Biotech, AL, USA). Flow cytometric analysis was per-
formed on a BD LSR Fortessa X20 Analyser and analysed using FlowJo software.
Immunohistochemistry. Sections (4 μm) of formalin-fixed paraffin-embedded spleens isolated from 4- 
and 12-week-old eYFP-Osx:Cre, eYFP-Rptorob+/− and eYFP-Rptorob−/− mice (n = 8–10 per group) were stained 
with haematoxylin and eosin. Histomorphometric analysis of white pulp area, total spleen area and follicle num-
ber was performed using the OsteoMeasure XP system (Osteometrics Inc., GA, USA). For quantitative assess-
ment of white pulp area, follicle number and follicle size between mouse cohorts, values were normalised to total 
spleen area in order to account for the reduced spleen size of eYFP-Rptorob−/− mice.
Isolation of eYFP+ cells and real-time PCR. Compact bone cells (CB-MSCs) were obtained from the 
long bones of 4-week-old eYFP-Osx:Cre, eYFP-Rptorob+/− and eYFP-Raptorob−/− mice in accordance to pub-
lished methods41. In brief, femora and tibiae from 8–12 mice were excised, cleaned thoroughly then crushed 
in ice-cold phosphate buffered saline (PBS) supplemented with 2% FCS and 2 mM EDTA, washed several 
times, chopped into small fragments and digested in 3 mg/mL Type 1 collagenase (Worthington Biochemical 
Corporation, NJ, USA) at 37 °C for 45 minutes with shaking. The resulting cell suspension was filtered through 
a 70 μm strainer then eYFP+ cells isolated by FACS using a MoFlo® Astrios™ (Beckman Coulter, CA, USA). 
Total RNA was isolated from eYFP+ cells using the RNAqueous-Micro kit (Life Technologies, Melbourne, 
Australia) and cDNA prepared from 70 ng of total RNA using Sensiscript reverse transcriptase as per the man-
ufacturers’ instructions (Qiagen). Real-time PCR reactions were performed using RT2 SYBR Green ROX rea-
gent (Qiagen) in Rotor-Gene 3000 thermo-cycler (Corbett Research, Qiagen). Primer sets used in this study: 
β-actin: Fwd 5′-ttgctgacaggatgcagaag-3′; Rev 5′-aagggtgtaaaacgcagctc-3′, Cxcl12: Fwd 5′-gtcctcttgctgtccagctc-3′; 
Rev 5′-gtctgttgttgttcttcagcc-3′, Il-7: Fwd 5′-attatgggtggtgagagccg-3′; Rev 5′-gttcctgtcattttgtccaattca-3′. Changes in 
gene expression were calculated relative to β-actin using the 2−∆∆Ct method42.
ELISA. Circulating levels of CXCL12 and IL-7 were measured in serum samples collected from 4- and 
12-week-old animals using commercial murine-specific immunoassay kits as per manufacturer’s instructions 
(R&D Systems, MN, USA).
Calvarial MSC Isolation. Primary calvarial MSCs were isolated from 4-day old RosaRaptorfl/fl mice as pre-
viously described43. Briefly, calvariae excised from 4 litters of mice were pooled, washed with PBS and digested in 
2 mg/mL Type 2 collagenase at 37 °C (Worthington Biochemical Corporation) for 20 minutes on a shaking platform. 
The resultant cell suspension was pelleted by centrifugation. Fresh collagenase was added to the calvariae for an 
additional 20 minutes and the resultant cell suspension was pooled with the cells from the first round of digestion.
Calvarial MSCs were cultured in α-MEM supplemented with 20% FCS, 2 mM L-glutamine, 100 µM 
L-ascorbate-2-phosphate, 50 IU/mL penicillin, 50 μg/mL streptomycin sulphate, 1 mM sodium pyruvate and 
15 mM HEPES (Sigma Aldrich, NSW, Australia) in a hypoxic in vitro cabinet (5% O2, 10% CO2, 85% N2, Coy 
Laboratory Products, MI, USA) at 37 °C41. Cells were passaged by detachment with a 0.05% trypsin-EDTA solu-
tion upon reaching 80–90% confluence.
Cre-mediated gene deletion. Calvarial MSCs (passages 2–3) were infected with a lentivirus carrying a 
tamoxifen-inducible self-deleting Cre recombinase (LEGO-CreERT2-iG2)44 as previously described45. Calvarial 
MSCs with stable lentiviral integration were selected on the basis of GFP expression. Following in vitro expansion, 
cells were treated with 0.5 μM 4-hydroxytamoxifen (4-OHT, Sigma Aldrich) for 8 days to induce Rptor deletion 
(RapKO cells). Ethanol (0.05%) was used as a vehicle control.
Osteoblast/haematopoietic cell co-culture. Osteoblastic differentiation of calvarial MSCs was induced 
by the addition of 10 mM β-glycerol phosphate (Sigma), 50 μM ascorbate-2-phosphate, 10−7 M dexamethasone 
and 100 ng/mL human BMP-2 in 10% FCS/α-MEM for 5–6 days until the cells reached confluence, followed by 
digestion and replating in the presence of 10 mM β-glycerol phosphate, 50 μM ascorbate-2-phosphate and 10−7 M 
rat PTH (Sigma Aldrich) for 7–10 days, until the cells reached confluence and formed a gel-like collagen pad6.
BM Lin-Sca-1+c-kit+ (LSK) cells from wild type mice were used as a source of primary HSCs. Briefly, whole 
BM cells were flushed from the femurs and tibias, blocked with mouse γ-globulin (Jackson Immunoresearch) and 
stained with a cocktail of biotinylated antibodies to mature haematopoietic cell markers (CD3, CD4, CD5, CD8, 
CD11b, Gr-1, B220, Ter-119; BioLegend), Sca1-PE-Cy7 (BD Bioscience), c-kit APC (eBioscience), and fluorogold 
(Abcam, Cambridge, UK) to exclude non-viable cells. Fluorescence Activated Cell Sorting (FACS) was performed 
to collect LSK cells (FACSAriaIII, Becton Dickinson).
LSK cells (1000 cells/well) were seeded onto monolayers of pre-cultured osteoblasts with or without cytokines 
(30 ng/mL mIL-7, 30 ng/mL mFlt-3L and 200 ng/mL mCXCL12, R&D Systems) in 10% FCS/α-MEM containing 
50 μM ascorbate-2-phosphate and 10 mM β-glycerol phosphate, and co-cultured for 10 days. On day 5, media was 
changed and fresh IL-7 and Flt-3L added to cytokine-treated wells. After 10 days, cells were stained using antibodies 
directed against B220, IgM, CD43 and CD19 (as described above) and analysed on a BD LSR Fortessa X20 Analyser.
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Statistical analysis. All data are presented as mean ± standard error of the mean (SEM). Statistical sig-
nificance was determined by one-way or two-way ANOVA with Tukey’s post-hoc test using GraphPad Prism 
(Version 6.0; GraphPad Software Inc, CA, USA). In all cases, p < 0.05 was considered statistically significant.
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